Bioprocess Automation Market (2025 - 2033)

Bioprocess Automation Market Summary

The global bioprocess automation market size was estimated at USD 7.76 billion in 2024 and is projected to reach USD 22.41 billion by 2033, growing at a CAGR of 12.67% from 2025 to 2033, driven by rising demand for biologics, advancements in AI and robotics, and the need for regulatory compliance and efficiency.

Rising Demand for Biologics

The rising demand for biologics is among the most significant drivers of the bioprocess automation industry. Over the past decade, there has been a sharp increase in the development and use of monoclonal antibodies, vaccines, gene therapies, and other biologic products due to their effectiveness in treating complex diseases, including cancer, autoimmune disorders, and rare genetic conditions. For these biologics to remain effective and to maintain high quality, manufacturing procedures must be extremely controlled, scalable, and precise. There is a significant need for fully automated bioprocess solutions because traditional manual or semi-automated production methods are frequently labor-intensive, prone to mistakes, and inadequate to meet the expanding market demand.

Correlation of total drug approvals vs. biologics approvals by the FDA

Source: Biomedicines Secondary Research, Grand View Research

The need for bioprocess automation is anticipated to increase as the world's healthcare system depends more on biology for novel treatments, making it an essential part of contemporary pharmaceutical production. Automation in bioprocessing allows manufacturers to optimize production workflows, improve consistency, and increase throughput without compromising quality. Biopharmaceutical companies can produce larger biologics with reduced variability, faster turnaround times, and lower operational costs by integrating robotics, AI, and advanced monitoring systems.

Need for Efficiency and Cost Reduction

The need for cost and efficiency reduction largely drives the market for bioprocess automation. Manufacturing biopharmaceuticals is a complicated and resource-intensive process that frequently requires highly qualified staff, careful observation, and strict protocol adherence. Batch failures, inconsistent products, and higher production costs can result from labor-intensive, human error-prone manual or semi-automated processes. By implementing automated systems, businesses can increase productivity, decrease reliance on manual labor, and minimize errors, guaranteeing more consistent and dependable results across production batches.

Automation increases productivity, drastically reduces operating costs, and improves reliability. Manufacturers can more effectively meet growing market demand thanks to automated bioprocessing systems' ability to run continuously with little downtime, optimize resource usage, and speed up production cycles. In an increasingly cost-sensitive healthcare environment, the ability to produce high-quality biologics at a lower cost also helps businesses stay competitive. As a result, the need for cost-effectiveness and operational efficiency keeps driving global investments in bioprocess automation technologies.

Market Concentration & Characteristics

The degree of innovation in the bioprocess automation industry is a key driver shaping its rapid growth. Advances in robotics, artificial intelligence (AI), machine learning, and the Internet of Things (IoT) enable highly sophisticated, integrated systems that can monitor and control complex bioprocesses in real time. These developments lower variability and enhance product quality by allowing adaptive control, process optimization, and predictive analytics. In addition, manufacturers can swiftly scale production or adjust to new biologics, gene therapies, and personalized medicines thanks to the emergence of modular and flexible automation platforms.

The bioprocess automation industry is witnessing a moderate to high level of mergers and acquisitions (M&A) activity, as major players seek to expand their technological capabilities, product portfolios, and global reach. To develop their knowledge of AI, robotics, and digital biomanufacturing, well-known bioprocess solution providers are purchasing automation technology companies and specialized startups. Similarly, big biotech and pharmaceutical firms are hiring automation experts or collaborating with them to acquire cutting-edge platforms that improve production efficiency and compliance. For instance, in September 2025, Yokogawa Corporation and Repligen launched their partnership, integrating OpreX Bio Pilot with MAVERICK to enhance automated glucose and lactate monitoring in bioprocessing. As a result of the industry's drive for integrated and end-to-end solutions, M&A is now positioned as a strategic tool to boost innovation and preserve competitiveness in the quickly changing bioprocessing market.

Regulations significantly impact the bioprocess automation industry, as stringent guidelines govern biopharmaceutical manufacturing to ensure product safety, quality, and efficacy. Agencies like the U.S. FDA, EMA, and other global regulators require consistent adherence to Good Manufacturing Practices (GMP). This encourages businesses to implement automated systems that improve traceability, reduce human error, and guarantee compliance. Automation facilitates quicker regulatory approvals by supplying accurate, validated data and helps maintain standardized documentation and quality control.

Product expansion is a key driver in the bioprocess automation industry, as companies continuously develop advanced systems to meet the evolving needs of biopharmaceutical manufacturing. Numerous companies are also growing their product lines with AI-powered software, single-use devices, and end-to-end automation platforms designed for biologics, vaccines, and cell and gene therapies. Manufacturers can adopt innovative solutions that increase productivity, lower costs, and shorten time-to-market thanks to this ongoing expansion of product offerings, strengthening competitive positioning.

Regional expansion is emerging as a strong market driver in the bioprocess automation industry, as companies aim to strengthen their global presence and tap into high-growth regions. Leading players are expanding manufacturing facilities, R&D centers, and partnerships across Asia-Pacific, Latin America, and the Middle East, where rising investments in healthcare infrastructure and biomanufacturing are creating new opportunities. This global push for regional expansion diversifies revenue streams and positions companies closer to emerging markets, accelerating the adoption of automated bioprocess solutions worldwide.

Product & Service Insights

In 2024, the process automation hardware segment was the market leader with 30.36% share, as it witnessed extensive adoption of high-performance sensors, controllers, and monitoring systems, to achieve an accuracy of control for bioprocesses for near-real-time circumstances. The segment has been transformed by increasing demand for high-throughput operations, repeatability of product quality, and declining operational errors. Furthermore, the strong push of companies investing in revitalizing manufacturing infrastructure and leading to smart factories only serves to further the constant dominance across biopharmaceutical and biotechnological facilities.

The software and control systems segment is expected to grow at the fastest CAGR over the forecast period, because of the growing consumption of digital bioprocessing systems, real-time monitoring systems, and advanced analytics solutions that support process improvement and regulatory compliance. Integrating AI, machine learning, and cloud-based systems further drives demand by enabling predictive maintenance, automated decision-making, and optimization of production workflows.

Process Stage Insights

The upstream segment dominated the market in 2024 with a share of 34.91%, owing to its widespread adoption as a reliable and cost-effective cryopreservation method for a broad range of cell types. This technique minimizes ice crystal formation through controlled cooling rates, helping preserve cell viability and structural integrity during long-term storage. Its compatibility with various cryoprotective agents, ease of standardization, and suitability for research and clinical applications have reinforced its market leadership.

The quality control and PAT segment is anticipated to experience the fastest CAGR during the forecast period due to the increasing focus on regulatory compliance, real-time product monitoring, and consistent process validation. The growing use of PAT tools is supposed to help manufacturers improve product quality, reduce batch failures, and allow for economical production at scale. In addition, the increased complexity of biologics and cell and gene therapies is further propelling the demand for quality control.

End Use Insights

The pharmaceutical & biotech manufacturers segment captured the largest market share of 36.24% in 2024, owing to the expanding production of biologics, vaccines, and advanced therapies that need highly automated and efficient bioprocessing systems. This is driven by the need for large-scale, cost-effective, and compliant manufacturing processes, which have spurred pharma and biotech companies.

The CDMOs & CMOs segment is projected to grow at the fastest CAGR during the forecast period, driven by the current industry trend of moving bioprocessing functions into specialized service providers to save costs, build capacities, and accelerate time-to-market. Moreover, growing demand for more flexible styles of manufacturing and increased collaborations between pharmaceutical innovators with CMOs/CDMOs will drive the market.

Regional Insights

North America bioprocess automation industry dominated the global market with a share of 42.78% in 2024, supported by advanced healthcare infrastructure, strong R&D investment, and the presence of leading biopharmaceutical companies. Automation technology adoption has been accelerated by the region's established supply networks and a growing emphasis on precision medicine and the production of cell and gene therapies. The need for effective, scalable, and compliant bioprocess solutions will support revenue growth in the upcoming years due to the growing elderly population and the rising disease prevalence.

U.S. Bioprocess Automation Market Trends

The U.S. bioprocess automation industry remains highly competitive, driven by robust investments in biopharmaceutical R&D, leadership in regenerative medicine, and an expanding pipeline of advanced biologics. The country has rapidly adopted process control systems, robotics, and AI-driven monitoring platforms to streamline production of large-scale cell and gene therapy. Rising demand for scalable biomanufacturing, particularly in oncology and rare diseases, positions the U.S. as the global hub for bioprocess automation innovation. For instance, in May 2025, Made Scientific partnered with Orchestra Life Sciences in the United States to expand its Princeton, New Jersey, cell-therapy manufacturing facility, adding 12,000 square feet to support late-phase and commercial demand.

Europe Bioprocess Automation Market Trends

The bioprocess automation industry in Europe is experiencing steady growth, fueled by government funding, Horizon Europe research programs, and increasing adoption of digitalized biomanufacturing platforms. The EMA's strict compliance framework has promoted widespread automation for consistency and quality. With end-to-end automation systems and software for sophisticated process control, major players like Sartorius, Merck KGaA, and Cytiva are growing their portfolios. Europe's leadership in automation-enabled bioprocessing is strengthened by the growing adoption of biobanking, cell-based therapies, and cross-border partnerships.

The UK bioprocess automation market is expanding with a strong biomedical research base, advanced academic-industry collaborations, and cell and gene therapy manufacturing leadership. Regulatory oversight by the MHRA and investments in the UK Biobank program have accelerated automation adoption. Initiatives such as the NHS’s integration of next-generation therapies underscore the growing reliance on automated platforms for large-scale, GMP-compliant biomanufacturing. For instance, in July 2025, partners from Canada and the United Kingdom launched the BALANCE project, a USD 2 million AI-powered bioreactor collaboration integrating automation, sensing, and digital twins to transform biologics manufacturing efficiency and scalability.

Germany's bioprocess automation market is supported by a robust pharmaceutical industry, strong research institutes, and government-backed innovation programs. The nation's emphasis on regenerative therapies and precision medicine has fueled the use of digital twins, automated bioreactors, and smart manufacturing systems. For instance, in April 2022, Merck improved its BioContinuum Platform and advanced integrated, data-driven bioprocessing capabilities to increase efficiency and lower costs by purchasing the MAST automated bioreactor sampling platform from Lonza. Strict Paul-Ehrlich-Institut rules guarantee adherence, and domestic and foreign businesses spend money on automated, scalable solutions to bolster Germany's standing as a European center.

Asia Pacific Bioprocess Automation Market Trends

Asia Pacific bioprocess automation industry is projected to grow at the fastest CAGR of over 14.96% during the forecast period, driven by government initiatives, cost-effective labor, and rapid biologics manufacturing expansion. To improve the production of monoclonal antibodies, vaccine development, and personalized medicine manufacturing, nations such as China, India, Japan, and South Korea are investing more in sophisticated automation platforms.

China bioprocess automation market is rapidly emerging as a global leader, supported by major investments in biotechnology and automation under initiatives such as “Made in China 2025.” The adoption of GMP-compliant automation systems has been accelerated by the government's drive for innovation and the NMPA's changing regulatory standards. Expanding cell therapy pipelines, large-scale biomanufacturing facilities, and academic-industry collaborations are positioning China as one of the fastest-growing automation markets.

Bioprocess automation market in Japan remains a pioneer in regenerative medicine and stem cell research, particularly iPSC technologies, driving automation adoption across academic and industrial labs. Japan's continued leadership in regenerative medicine and stem cell research, specifically in the area of iPSC technologies, is encouraging businesses to incorporate robotics, process monitoring, and digital control platforms into production workflows. AMED's supportive policies and advantageous PMDA regulations encourage businesses to incorporate robotics, process monitoring, and digital control platforms into production workflows.

MEA Bioprocess Automation Market Trends

The Middle East and Africa (MEA) bioprocess automation industry is still in its infancy, but it has a lot of promise thanks to investments in biomanufacturing facilities, medical research, and healthcare infrastructure. Through government-sponsored programs and public-private partnerships, nations such as United Arab Emirates, Saudi Arabia, and South Africa are spearheading the adoption of automated platforms. The growing demand for precision therapies, personalized medicine, and advanced manufacturing technologies is driving the region's slow but steady adoption of bioprocess automation.

Kuwait bioprocess automation market is a developing industry where automation adoption is fueled by healthcare modernization, growing biomedical research initiatives, and growing awareness of advanced therapies. Government investments in healthcare digitization and partnerships with international bioprocess technology suppliers make GMP-compliant automation systems possible. Although still nascent, Kuwait is positioning itself as a growing contributor to the regional bioprocess automation market.

Key Bioprocess Automation Company Insights

Several well-established companies control most of the bioprocess automation industry. They maintain this control by maintaining strong product portfolios, forming strategic alliances, and consistently investing in R&D. With their sophisticated automation technologies, integrated bioprocess platforms, and extensive global distribution networks that support large-scale biomanufacturing and research applications, industry leaders like Thermo Fisher Scientific Inc., Sartorius AG, Parker Hannifin Corp, Danaher, Merck KGaA, and Eppendorf SE command a substantial portion of the market.

By offering cutting-edge automation solutions, modular systems, and customizable platforms that meet the rising demand for scalable, effective, and compliant bioprocess operations, businesses like SIA Bioreactors.net, Senieer, and Getinge are extending their reach. These companies cater to research institutions, biopharmaceutical manufacturers, and gene and cell therapy developers looking for dependable, end-to-end automation solutions.

The market for bioprocess automation is expanding rapidly thanks to targeted M&A activity, strategic partnerships, and technological breakthroughs. Businesses that successfully combine cutting-edge process automation with customer-focused solutions will be in a strong position to benefit from this quickly changing industry, increasing biopharmaceutical manufacturing's productivity, compliance, and scalability globally.

Recent Developments

• In June 2025, Sartorius Stedim Biotech completed a major expansion at its Aubagne, France headquarters, nearly doubling cleanroom and lab space, adding automated production and logistics systems, and enhancing R&D for innovative bioprocess solutions.

• In December 2024, Getinge partnered with 908 Devices in Sweden to integrate MAVEN with Getinge bioreactors, enabling continuous, real-time monitoring and automated control of glucose and lactate in cell cultures.

Bioprocess Automation Market